617 results on '"Gardin, Claude"'
Search Results
2. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
3. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
4. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia
5. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells
6. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
7. P961: BORTEZOMIB, RITUXIMAB AND DEXAMETHASONE REGIMEN (BDR) IN WALDENSTRÖM MACROGLOBULINEMIA: A RETROSPECTIVE ANALYSIS
8. UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia
9. Abstract 464: AAC-11 survival pathways as therapeutic target in cancer: AAC-11 leucine-zipper domain derived peptides exert potent antitumor effects and exhibit favorable stability, pharmacokinetic and toxicology profiles
10. Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review
11. Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively
12. Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL)
13. Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study
14. Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group
15. Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia
16. An update of current treatments for adult acute myeloid leukemia
17. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure
18. Azacitidine for the treatment of relapsed and refractory AML in older patients
19. Hypomethylating Agents as a Therapy for AML
20. UBTFtandem duplications define a distinct subtype of adult de novo acute myeloid leukemia
21. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial
22. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia
23. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)
24. Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study
25. Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study
26. Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study
27. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
28. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
29. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
30. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study
31. Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis
32. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience
33. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy
34. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
35. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study
36. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
37. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study
38. Azacitidine in untreated acute myeloid leukemia: A report on 149 patients
39. Outcome of older patients with acute myeloid leukemia in first relapse
40. Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS
41. Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup
42. BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias
43. Abstract 608: The MPS1 inhibitor S81694 is active in acute myeloid leukemia (AML)
44. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure
45. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70-year old: A phase 1/2 study of the acute leukemia French association
46. Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: Delineation of anti-leukemic mechanisms of action
47. Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)
48. Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML
49. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study
50. JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.